Number of the records: 1
SKLB1002, a novel inhibitor of VEGF receptor 2 signaling, induces vascular normalization to improve systemically administered chemotherapy efficacy
SYS 0085161 LBL 00000naa--2200000-a-4500 005 20250607144611.1 008 130226c2012----xo-----e------------eng-- 040 $a BA006 $b slo 041 0-
$a eng $b eng 044 $a xo $c SK 242 10
$a SKLB1002, nový inhibítor VEGFR 2 receptora signalizácie, indukuje normalizáciu vaskulatúry a cielene zvyšuje účinnosť systémovo podávanej chemoterapie $y slo 245 10
$a SKLB1002, a novel inhibitor of VEGF receptor 2 signaling, induces vascular normalization to improve systemically administered chemotherapy efficacy / $c G. Shen ... [et al.] 300 $b ilustr., grafy, obr. 504 $a Bibliogr. odkazy 504 $a Res. angl. 650 12
$7 sllk_us_auth*d009374 $a nádory experimentálne $x farmakoterapia $x patológia $2 mesh 650 22
$7 sllk_us_auth*d042442 $a faktory rastové endotelové cievne $2 mesh 650 22
$7 sllk_us_auth*d020533 $a inhibítory angiogenézy $2 mesh 650 12
$7 sllk_us_auth*d040301 $a receptor 2 pre cievny endotelový rastový faktor $x antagonisty a inhibítory $x použitie terapeutické $2 mesh 650 22
$7 sllk_us_auth*d009389 $a neovaskularizácia patologická $2 mesh 650 22
$7 sllk_us_auth*d055806 $a mikrocievy $x účinky liekov $2 mesh 650 12
$7 sllk_us_auth*d009362 $a metastázy nádorové $x ultraštruktúra $2 mesh 650 22
$7 sllk_us_auth*d015687 $a hypoxia bunková $x účinky liekov $2 mesh 650 22
$7 sllk_us_auth*d004317 $a doxorubicín $2 mesh 650 22
$7 sllk_us_auth*d023421 $a modely zvieracie $2 mesh 653 2-
$a chemoterapia 653 2-
$a vaskulatúra nádoru 700 1-
$7 sllk_us_auth*0028530 $a Shen, G. $4 aut 700 1-
$7 sllk_us_auth*0028531 $a Li, Y. $4 aut 700 1-
$7 sllk_us_auth*0028532 $a Du, T. $4 aut 700 1-
$7 sllk_us_auth*0027671 $a Shi, G. $4 aut 700 1-
$7 sllk_us_auth*0022698 $a Dai, L. $u State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, the People's Republic of China $4 aut 700 1-
$7 sllk_us_auth*0022691 $a Chen, X. $u State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, the People's Republic of China $4 aut 700 1-
$7 sllk_us_auth*0028533 $a Zheng, R. $4 aut 700 1-
$7 sllk_us_auth*0028534 $a Li, W. $4 aut 700 1-
$7 sllk_us_auth*0028535 $a Su, X. $4 aut 700 1-
$7 sllk_us_auth*0022688 $a Zhang, S. $u State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, the People's Republic of China $4 aut 700 1-
$7 sllk_us_auth*0022699 $a Wei, Y. $u State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, the People's Republic of China $4 aut 700 1-
$7 sllk_us_auth*0028536 $a Yang, S. $4 aut 700 1-
$7 sllk_us_auth*0022700 $a Deng, H. $u State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, the People's Republic of China $4 aut 773 0-
$7 nnas $w sllk_us_cat*0079255 $t Neoplasma $f Cancer Research Institute of the Slovak Academy of Sciences $x 0028-2685 $d Bratislava : AEPress, 2012 $g Vol. 59, no. 5 (2012), s. 486-493
Number of the records: 1